Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity Biotech Investing
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Biotech Investing
RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review Biotech Investing
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones Biotech Investing
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B Biotech Investing
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone Biotech Investing
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy Biotech Investing
PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine ) Biotech Investing
Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Biotech Investing
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Biotech Investing
